capricor.com (CAPR) - מזומנים למניה אחת

Capricor Therapeutics (CAPR) pays no dividends, as biotech development depends on science rather than economic cycles. Cash per share serves as a metric of confidence, where the value 3.39 acts as a baseline liquidity indicator. High demand for the CAP-1002 platform provides pricing power, while a strategic alliance with a distributor accelerates the time-to-market for its drugs.
פילוחי מדדים מקיפים ואנליטיקה עבור Capricor Therapeutics, Inc. (CAPR)

To objectively evaluate an issuer, it is essential for a portfolio manager to understand the company's liquid reserves, which this indicator calculates as the ratio of total cash to the number of shares outstanding. Analyzing the cash per share for the security allows for an assessment of the financial stability of Capricor Therapeutics (CAPR) during the development of the CAP-1002 platform, whose value is increasing due to inelastic demand for Duchenne muscular dystrophy treatment.